The U.S. Food and Drug Administration approved the use of lumacaftor/ivacaftor (Orkambi®) today for children with cystic fibrosis ages 2 to 5 who have two copies of the F508del mutation.
Site Search
Showing 51 - 60 of 259 results
News
|
|
2 min read
News
|
|
2 min read
News
|
|
2 min read
News
|
|
1 min read
News
|
|
1 min read
News
|
|
1 min read
News
|
|
2 min read
News
|
|
2 min read
News
|
|
3 min read